Our data are in line with previous studies that have shown enhancement of radiation effects with intratumoral STING agonist injection (e.g. cGAMP or RR-CDG)20,57, but our findings of successful i.v. administration suggest a path for rapid integration into standard HNSCC radiation treatment regimens. This evidence concerns the gene STING1 and head and neck squamous cell carcinoma.